Jimin Lee

This study identifies sex-specific molecular targets in Parkinson's disease through multi-omic integration, revealing sexually dimorphic pathways and gene associations.

The paper shows repeated SARS-CoV-2 vaccine boosters elicit variant-specific memory B cells and neutralizing antibodies, suggesting immune imprinting can be overcome with updated vaccines.

This paper describes a miniprotein inhibitor that neutralizes multiple SARS-CoV-2 variants and protects mice against them when administered post-exposure.

This paper develops an mRNA-launched nanoparticle vaccine that combines protein nanoparticle and mRNA vaccine advantages, showing enhanced antibody and T cell responses in mice.

This study designs miniproteins that inhibit MERS-CoV by targeting the spike protein, showing broad neutralization and protective efficacy in mice.

This paper designs multivalent RBD nanoparticle vaccines that overcome immune imprinting and provide broad protection against SARS-CoV-2 variants and sarbecoviruses.

This study shows SARS-CoV-2 nsp1 inhibits translation in bat cells and human cells, revealing its broad activity across mammals.

HKU5 merbecoviruses use bat Pipistrellus abramus ACE2 and several artiodactyl ACE2s through a cryo-EM-defined binding mode distinct from other ACE2-using coronaviruses, showing independent evolution of ACE2 usage.

The paper identifies two European bat MERS-related coronaviruses that use ACE2 as their receptor, revealing a distinct binding mode and host tropism determinants.

This study identifies molecular mechanisms of FCoV-23 pathogenicity, including receptor usage and biotype switching, and identifies a cross-reactive antibody for therapeutic development.

This study uses deep mutational scanning to assess how mutations in SARS-CoV-2 spike proteins affect ACE2 binding, cell entry, and serum escape, linking these effects to clade growth rates.

This paper develops a stabilization strategy for sarbecovirus fusion machinery vaccines, showing broad reactivity and protection against SARS-CoV-2 variants.

This study characterizes the receptor tropism and antigenicity of a clade 3 sarbecovirus, identifying broad ACE2 usage and cross-neutralizing antibodies with implications for vaccine design.